dailynewsnblog
“For patients living with heart failure, reducing hospitalizations and maintaining or improving functional status and quality of life is a meaningful clinical goal,” said Rami Kahwash, MD, Heart Failure Cardiologist and Professor of Medicine at The Ohio State University Wexner Medical Center. Dr. Kahwash, the National Principal Investigator of the Post-Approval Study, presented the data at the HFSA late-breaker. “As newer medications continue to reshape the real-world treatment landscape, a large proportion of these patients were receiving ARNi and SGLT2i therapies, which are known to dramatically decrease risk. Despite this, CCM® Therapy continued to deliver meaningful and sustained improvements in functional capacity, symptoms and clinical outcomes.”
